---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-254149"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2021-08-23T23:59:59+00:00"
generated_at: "2026-06-29T08:26:22.636890+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BridgeBio appoints Fred Hassan, Andrea Ellis, and Douglas Dachille to board of directors

## Summary
- Board expanded from 11 to 14 members; three new independent directors effective August 17, 2021.
- Fred Hassan, former Schering-Plough CEO and Warburg Pincus director, appointed as Class II director.
- Andrea Ellis, CFO of Lime and former Goldman Sachs banker, appointed as Class II director and audit committee member.
- Douglas Dachille, former AIG CIO, appointed as Class III director; previously served as board observer.
- Each director granted option to purchase $1.2M of common stock at $49.54, vesting over three years.

## SEC filing metadata
- accession: 0001193125-21-254149
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2021-08-23T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/d219643d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-254149
- JSON: https://secwatch.observer/filing/0001193125-21-254149.json
- Plain text: https://secwatch.observer/filing/0001193125-21-254149.txt

## Key facts
- Executive change
  Fred Hassan was appointed as Director at BridgeBio Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm
- Executive change
  Andrea Ellis was appointed as Director at BridgeBio Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm
- Executive change
  Douglas Dachille was appointed as Director at BridgeBio Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.